Skip to main content
Business

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Feed excerpt — reported by MarketWatch

The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →

Original Source

This article was syndicated from MarketWatch. All rights remain with the original publisher.